Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
about
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerNot all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategySpotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsNew developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceAfatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFRTyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysThird-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerClinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting.Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions.Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.Privileged Electrophile Sensors: A Resource for Covalent Drug Development.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.Recent developments in nanomedicine for melanoma treatment.Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.Safety of gefitinib in non-small cell lung cancer treatment.Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
P2860
Q26740529-002E6AB4-8993-43AD-8557-47CAC18EF64AQ26744284-1E54543F-6338-446C-911D-C3A8374FC532Q26745776-5FAE998B-2076-4C40-94F0-5EF919E9E05AQ26747276-EBED6BA3-3703-4891-8FF2-406C5C603453Q28075291-C80CA6F7-C381-464C-BDB5-6874A16AC8EFQ28075511-067E9B5D-2657-464F-AEB6-F8B6081FECCFQ28079320-5CABB80E-D6C6-4CF0-8817-34F51B236701Q31160116-A6D5008B-8698-48E0-BEC3-0A8AFDF6CC2AQ33618558-1FECB522-CB85-4611-85F5-34C02D046907Q33662730-A96017CE-4960-4B15-B0A2-E426A2B047ADQ33704088-0594DD83-337C-406C-A1E1-3811E550C2A2Q33737298-D01A3F5B-F70B-4AF3-BAA5-9C2486277F9CQ33740707-114EDF9D-33F0-4647-8743-8B81C9A7DFA9Q33779181-F405FCA2-11C8-4D06-B1B3-755B4B011256Q36132436-89352F52-320D-4E59-9ADC-E9E4F5075F2CQ36224645-20C87AFB-453F-449C-A36B-AC51C3926C5FQ36372611-85049A29-D211-4C3E-B59C-AD5A23FC0FACQ37060709-D9D3EF06-3D38-461D-8962-578A6B4CDADCQ37528312-05F0D708-E291-4B62-8B18-49836D9E5D03Q37572972-A01CDE81-8A80-47BC-8809-C6CAF4AE0DC3Q37578362-A5674157-DDB2-44EB-B43E-41B89780AD44Q37637905-D53A590E-7A61-4F11-84E8-28E94A2963B9Q37695065-AAA1EFEC-F4D2-457B-9FF1-3E34EA496287Q37698613-FDFA093E-A1D4-4C0B-8009-1573D823A24CQ37702099-236AA207-397D-4028-937A-C5FCC3857A9AQ37708814-0BB06205-BA34-42B2-B112-DF22FC29A49EQ37742623-28372208-EBB9-44CF-9D01-2A6155082817Q38385682-14F1B257-F142-46AD-8B76-41FB94912C57Q38651333-00001311-56F2-43B0-8329-0011BD14529BQ38652369-5932EB8D-D5DA-42EE-A037-EE413A030E4EQ38665706-C0BA0E64-8106-4BB5-922D-12235E7E4007Q38710055-877AB9B9-2A39-4151-AB40-AB76DFA4C6FBQ38720801-0DC6BD17-F021-48C3-BED3-CBD704715658Q38740124-B7C22DC9-BE57-4B9F-A3A4-5EC913931100Q38821624-E06487EE-1EFF-414B-93DE-85D949FA660CQ38829087-B796799D-E28D-418D-8111-931F0181AA88Q38829545-9E6AC52B-C304-4739-8F28-C26F7B7E6240Q38832105-21B68891-640A-464E-BB34-675D04C48813Q38841473-11104393-A97A-4DD3-80E0-F836DC28A440Q38845975-3D33CD88-F914-407D-8B67-70057B20961A
P2860
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Afatinib versus gefitinib as f ...... , randomised controlled trial.
@en
type
label
Afatinib versus gefitinib as f ...... , randomised controlled trial.
@en
prefLabel
Afatinib versus gefitinib as f ...... , randomised controlled trial.
@en
P2093
P50
P1433
P1476
Afatinib versus gefitinib as f ...... , randomised controlled trial.
@en
P2093
Catherine Dubos Arvis
Chun-Ming Tsai
Dan Massey
Dong-Wan Kim
Eng-Huat Tan
Janessa Laskin
Karl Kölbeck
Ken O'Byrne
Keunchil Park
P304
P356
10.1016/S1470-2045(16)30033-X
P577
2016-04-12T00:00:00Z